Annual report pursuant to Section 13 and 15(d)

Consolidated Statements Of Stockholders' Equity

v2.4.0.6
Consolidated Statements Of Stockholders' Equity (USD $)
In Thousands
Class A Common Stock
Class B Common Stock
Additional Paid-In Capital [Member]
Cumulative Translation Adjustment [Member]
Accumulated Deficit [Member]
Treasury Stock [Member]
Total
Balance at Mar. 31, 2009 $ 539 $ 147 $ 397,242 $ (206) $ (319,370) $ (1,904) $ 76,448
Net income         10,327   10,327
Translation adjustment       851     851
Options exercised 0   4       4
Treasury stock (12)   (19)     (1,398) (1,429)
Restricted stock grant, net of forfeitures 1           1
Stock-based compensation     1,529       1,529
Balance at Mar. 31, 2010 528 147 398,756 645 (309,043) (3,302) 87,731
Net income         67,936   67,936
Translation adjustment       320     320
Options exercised 15   2,601       2,616
Treasury stock (4)   (5)     (552) (561)
Restricted stock grant, net of forfeitures 1           1
Stock-based compensation     1,021       1,021
Class B stock converted to Class A stock 1 (1)          
Deconsolidation of Contineo         253   253
Repurchase of subsidiary stock options     (36)       (36)
Balance at Mar. 31, 2011 541 146 402,337 965 (240,854) (3,854) 159,281 [1]
Net income         41,982   41,982
Translation adjustment       (346)     (346)
Options exercised 9   1,675       1,684
Treasury stock (66)         (17,319) (17,385)
Restricted stock grant, net of forfeitures (1)           (1)
Conversion of RSUs to restricted stock 14   (14)       0
Tax benefits related to stock-based compensation     61       61
Stock-based compensation     1,205       1,205
Class B stock converted to Class A stock 7 (7)          
Repurchase of subsidiary stock options     (117)       (117)
Balance at Mar. 31, 2012 $ 504 $ 139 $ 405,147 $ 619 $ (198,872) $ (21,173) $ 186,364
[1] The balance sheet as of March 31, 2011 includes the balances of ConferencePlus. As disclosed in Note 1, the Company completed the sale of ConferencePlus on December 31, 2011. See Note 1 for additional information.